Goldman Sachs Group Inc X4 Pharmaceuticals, Inc Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 477,638 shares of XFOR stock, worth $229,266. This represents 0.0% of its overall portfolio holdings.

Number of Shares

477,638

Previous 292,585 63.25%

Holding current value

$229,266

Previous $196,000 87.24%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$0.28 - $0.82 $51,814 - $151,743	185,053 Added 63.25%	477,638 $367,000
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $65,553 - $104,399	121,395 Added 70.91%	292,585 $196,000
Q2 2024 Aug 13, 2024	SELL	$0.58 - $1.47 $514,889 - $1.3 Million	-887,740 Reduced 83.83%	171,190 $99,000
Q1 2024 May 15, 2024	BUY	$0.72 - $1.46 $710,022 - $1.44 Million	986,142 Added 1354.81%	1,058,930 $1.47 Million
Q4 2023 Feb 13, 2024	BUY	$0.61 - $0.99 $14,148 - $22,963	23,195 Added 46.77%	72,788 $61,000
Q3 2023 May 14, 2024	SELL	$1.03 - $2.02 $23,890 - $46,853	-23,195 Reduced 31.87%	49,593 $54,000
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $293,393 - $575,392	-284,848 Reduced 85.17%	49,593 $54,000
Q2 2023 May 14, 2024	BUY	$0.82 - $2.49 $205,786 - $624,887	250,959 Added 300.61%	334,441 $648,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $205,786 - $624,887	250,959 Added 300.61%	334,441 $648,000
Q1 2023 May 14, 2024	BUY	$0.8 - $1.22 $22,801 - $34,772	28,502 Added 51.84%	83,482 $72,000
Q1 2023 May 11, 2023	BUY	$0.8 - $1.22 $22,801 - $34,772	28,502 Added 51.84%	83,482 $72,000
Q4 2022 May 14, 2024	SELL	$0.69 - $2.21 $276 - $884	-400 Reduced 0.72%	54,980 $54,000
Q4 2022 Feb 13, 2023	SELL	$0.69 - $2.21 $276 - $884	-400 Reduced 0.72%	54,980 $54,000
Q3 2022 May 14, 2024	SELL	$0.89 - $1.71 $15,493 - $29,767	-17,408 Reduced 23.92%	55,380 $95,000
Q3 2022 Nov 10, 2022	BUY	$0.89 - $1.71 $49,288 - $94,699	55,380 New	55,380 $0
Q1 2022 May 16, 2022	SELL	$1.48 - $2.58 $31,004 - $54,048	-20,949 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.9 - $5.6 $19,900 - $58,654	10,474 Added 99.99%	20,949 $48,000
Q3 2021 Nov 10, 2021	BUY	$4.53 - $6.45 $47,451 - $67,563	10,475 New	10,475 $55,000

Others Institutions Holding XFOR

# of Institutions

Shares Held

99.6M

Call Options Held

421K

Put Options Held

80.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $33M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc X4 Pharmaceuticals, Inc Transaction History